Eddy Edson
Well-Known Member
- Relationship to Diabetes
- Type 2
The drug pipeline is delivering a bunch of new weight loss med candidates, as showcased at the current ADA scientific sessions.
This includes GLP-1/GIP/Glucagon receptor tri-agonists, with EliLilly releasing results for Retatrutide's Phase 2 trial today. Average of 24% weight loss at 48 weeks without reaching plateau. Mild-to-moderate transient gastro side-effects.
In other words: meds have reached the point where they look like they're about as effective for obesity as bariatric surgery.
This includes GLP-1/GIP/Glucagon receptor tri-agonists, with EliLilly releasing results for Retatrutide's Phase 2 trial today. Average of 24% weight loss at 48 weeks without reaching plateau. Mild-to-moderate transient gastro side-effects.
In other words: meds have reached the point where they look like they're about as effective for obesity as bariatric surgery.
Last edited: